Breach of Contract for a Branded Drug.An investment firm that owned the intellectual property rights to a branded drug brought suit against its partner, a pharmaceutical company. The investor plaintiff alleged that the defendant failed to uphold its obligations to manufacture and promote the drug. The plaintiff claimed that the defendant's failure led to supply interruptions and periods where the drug was not promoted to physicians, which irreversibly damaged the drug's long-term value.

how did the plaintiff claim that the defendant's actions irreversibly damaged the long-term value of the drug?